Logo

Genome Express Signs Partners on Mutacancer Program

Oct 28, 2005

NEW YORK, Oct. 28 (GenomeWeb News) - Genome Express will collaborate with France's Centre Léon Bérard in Lyon and the Centre Jean Perrin in Clermont Ferrand on the Mutacancer research program, the company said today.

 

Under the agreement, the Léon Bérard and the Jean Perrin centers gains access to the French company's technology and will keep the discoveries from the project. Genome Express will own any advances in screening technology.

 

Mutacancer, a sequencing program for mutational analysis of 300 gene candidates in human cancers, identifies diagnostic and therapeutic targets. The cancer diagnostics and therapeutics program targets breast, colon, and lung cancers.

 

Research results will be accessible to others in the healthcare sector, the partners said. They will consider offering joint services to the pharmaceutical industry.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.